EFG
VRTX icon

Ethos Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Ethos Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$224K Sell
464
-43
-8% -$19.1K 0.02% 547
2026
Q1 		$226K Sell
507
-4
-0.8% -$1.86K 0.02% 467
2025
Q4 		$232K Buy
+511
New +$220K 0.02% 439

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Ethos Financial Group's VRTX Position: Q2 2026 in Review

Ethos Financial Group reduced its Vertex Pharmaceuticals (VRTX) stake by 8.5% in Q2 2026, selling an estimated $19.1K and leaving 464 shares worth $224K. The position accounts for 0.02% of the portfolio, ranked #547.

Ethos Financial Group first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $232K in Q4 2025. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Ethos Financial Group held 464 shares of Vertex Pharmaceuticals worth $224K as of Q2 2026.
  • Ethos Financial Group sold 43 Vertex Pharmaceuticals shares in Q2 2026, an estimated $19.1K.
  • Vertex Pharmaceuticals made up 0.02% of Ethos Financial Group's portfolio in Q2 2026, its #547 holding.
  • Ethos Financial Group first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Ethos Financial Group's Vertex Pharmaceuticals position peaked at $232K in Q4 2025.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Ethos Financial Group's 13F filing for Q2 2026, filed 7 Aug 2026.